AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00853164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking exercise
Description: Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
Study NCT00853164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight training
Description: participants will be given a weight training prescription to do 3 times a week for eight weeks.
Study NCT00853164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
Study NCT03550833 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire
Study NCT01879839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet
Description: Patients receive special diet 4 days prior to contrast-agent administration.
Study NCT04290208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: IV Acetaminophen
Study NCT04290208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen liquid syrup
Study NCT04290208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Flavored, non-medicated (placebo) liquid syrup
Study NCT03439163 — intervention group
Intervention type: DEVICE
Intervention: MRI scan
Description: All participants underwent the MRI scan
Study NCT01871467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Study NCT02979379 — intervention group
Intervention type: OTHER
Intervention: Pain
Study NCT04290208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: IV salt solution (non-medicated)
Study NCT03550833 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 7 ml whole blood for Peripheral blood
Study NCT02749357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 minutes Lokomat
Description: 30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support.
Study NCT02749357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 60 minutes Lokomat
Description: 30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
Study NCT04230109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)
Study NCT03574155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Counseling and Education
Description: Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines.
Study NCT00752323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given orally
Study NCT00752323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection - 6 biopsies from 3 fluorescent regions
Study NCT03330756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic Roux-en-Y gastric bypass
Description: laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
Study NCT03330756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic Mini gastric bypass
Description: laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
Study NCT04230109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)
Study NCT04002245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antiseptic application
Description: The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
Study NCT00400660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK615915A
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
Study NCT01760421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
Study NCT00400660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo inhaler.
Study NCT01670981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ixmyelocel-T
Description: 12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
Study NCT01670981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
Study NCT02334566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NET TX
Description: Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
Study NCT02334566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET TX
Description: Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
Study NCT04670692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5G-MCE examination
Description: The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.
Study NCT04670692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCE examination
Description: The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
Study NCT01387555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594 recombinant vaccina GM-CSF
Description: Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
Study NCT01387555 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
Study NCT04194567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Ragi
Description: Pancakes made out of the dark ragi
Study NCT04194567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Ragi
Description: Pancakes made out of the white ragi
Study NCT02826200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Description: Standard of care plus oral anticoagulant therapy (acenocoumarol)
Study NCT02826200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care
Study NCT02826200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT02958592 — intervention group
Intervention type: OTHER
Intervention: two-dimensional shear-wave elastography (SWE)
Description: performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
Study NCT00779389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg will be taken once a day for 14-21days.
Study NCT00779389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Placebo
Description: Dasatinib (100 mg) once a day for 14-21 days.
Study NCT00779389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Dasatinib
Description: Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
Study NCT00779389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14-21 days.
Study NCT00779389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg for 14-21 days.
Study NCT04065100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sebum test
Description: Measuring sebum in newborn
Study NCT04065100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sebum test
Description: Measuring sebum in newborn
Study NCT03649620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: unripe Bokbunja Extract
Description: tablet(1 tablet/d, 600 mg/d) for 12 weeks
Study NCT03649620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: unripe Bokbunja Extract
Description: tablet(1 tablet/d, 600 mg/d) for 12 weeks
Study NCT00187681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2 doses of Metformin Day 1 1000mg, Day 2 850 mg
Study NCT01167673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coltect
Description: green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
Study NCT01167673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03604393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
Study NCT03649620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT03649620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT00995501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Sulfate
Description: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Study NCT00995501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin to maintain blood glucose 80-110 mg/dl.
Study NCT00995501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anesthesia management
Description: Light anesthesia to maintain BIS about 55
Study NCT00995501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone - placebo
Description: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Study NCT00995501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone - placebo
Description: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Study NCT00995501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin - Placebo
Description: Insulin to maintain blood glucose 180-200 mg/dl.
Study NCT00995501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin - Placebo
Description: Insulin to maintain blood glucose 180-200 mg/dl.
Study NCT02609620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peristaltic Feeding Tube
Study NCT02609620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConvaTec Levin Duodenal Tube
Study NCT00995501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia management -Placebo
Description: Deep anesthesia to maintain BIS about 35
Study NCT00995501 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia management -Placebo
Description: Deep anesthesia to maintain BIS about 35
Study NCT03076476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffolds (BVS)
Description: Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
Study NCT03076476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES) - slow
Description: Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS.
Study NCT03076476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-Eluting Stent (DES) - standard(std)
Description: Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
Study NCT03357614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem
Description: Antibiotic therapy for complicated UTI
Study NCT03357614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem-Etzadroxil/Probenecid
Description: Antibiotic therapy for complicated UTI
Study NCT03357614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Antibiotic therapy for complicated UTI
Study NCT03357614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Antibiotic therapy for complicated UTI
Study NCT03357614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Antibiotic therapy for complicated UTI
Study NCT03381261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Injection of Botulinum toxin type A in back of head
Study NCT01376323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 1mg
Description: GSK256073 1mg capsule
Study NCT01376323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 5mg
Description: GSK256073 5mg capsule
Study NCT01376323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 10mg
Description: GSK256073 10mg capsule
Study NCT01053663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu
Description: 10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
Study NCT02857244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
Study NCT02857244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil
Description: Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
Study NCT02857244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil
Description: Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil \& duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
Study NCT02211482 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dolutegravir, lamivudine
Description: single arm
Study NCT00971607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen + Sevoflurane
Description: Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
Study NCT00971607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (placebo)
Description: Control will receive oxygen only.
Study NCT00003416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00003416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00003416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00003416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT02683395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX51107
Study NCT01844648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH004 tropicamide
Description: Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
Study NCT01844648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NH004 Placebo
Description: Intra-oral slow dissolving muco-adhesive thin film
Study NCT04296825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Camel milk containing Bifidobacterium animalis A6
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Study NCT01376323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 25mg
Description: GSK256073 25mg capsule
Study NCT01376323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study NCT04296825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camel milk
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Study NCT04296825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis A6
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Study NCT04296825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow milk
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Study NCT01595009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus was supplied as tablets of 5mg strength.
Study NCT00684333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: painless subcutaneous injection by EZ-Ject Injector
Description: EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
Study NCT03882164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-Bile Ratio of Tacrolimus
Description: Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
Study NCT01919632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health-behavior seminar and endurance exercise
Description: The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
Study NCT03496870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone
Description: catechol-O-methyltransferase (COMT) inhibitor
Study NCT01376323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100mg capsule
Study NCT00454571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO
Study NCT00454571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Study NCT00454571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Study NCT03088124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Patients will take orally everyday 240 mg of Apalutamide.
Study NCT00454571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate
Study NCT00454571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Study NCT03496870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor